A Pharmacoeconomic Evaluation of Seven-Valent Pneumococcal Conjugate Vaccine in Spain

Value in Health

Volumn 7, Issue 1, 2004, Pages 36-51

  Asensi, Francisco ^a   De Jose, Maribel ^b   Lorente, Manuel ^c   Moraga, Fernando ^d   Ciuryla, Vincent ^e   Arikian, Steve ^f   Casciano, Roman ^f   Vento, Maximo ^g  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL TORRECÁRDENAS   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e PFIZER INC   (United States)

^f Analytica Group   (United States)

^g Hospital Virgen del Consuelo   (Spain)

Author keywords

Cost effective; PCV 7; Pneumococcal; Spain; Vaccination

Indexed keywords

HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG; VACCINE;

ARTICLE; CHILD; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG EFFICACY; ECONOMICS; EVALUATION; HEALTH CARE COST; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROBABILITY; SPAIN; STATISTICAL MODEL; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; VACCINATION;

EID: 0442309291     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2004.71263.x     Document Type: Article

References (53)

1. Centers for Disease Control. Prevention of pneumococcal disease: recommendations of the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep 1997;46(RR-8):1-31.
2. Fedson DS, Soubeyrand B. Expansion of pneumococcal vaccination in industrialized countries: will France join the movement? Presse Med 1998;27(Suppl 1):S50-4.
3. Black S. The Kaiser Permanente Efficacy Trial: Update on Otitis Media. Paper presented at The Second International Symposium of Pneumococci and Pneumococcal Disease; Sun City, South Africa, March 2000.
4. Shinefield H. The Kaiser Permanente Efficacy Trial: Update on Invasive Disease. Paper presented at the Second International Symposium of Pneumococci and Pneumococcal Disease; Sun City, South Africa, March 2000.
5. Black S, Shinefield H, Fireman R, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. The Northern California Kaiser Permanente Vaccine Study Group. Pediatr Infect Dis J 2000;19:187-95.
6. Dagan R, Melamed R, Muallem M, et al. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis 1996;174:1271-8.
7. Black SB, Shinefield HR, Hansen J, et al. Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2001;20:1105-7.
8. Fedson DS, Musher DM, Eskola J. Pneumococcal vaccine. In: Plokin SA, Orenstein WA, eds., Vaccines. 3rd ed. Philadelphia: Saunders, 1999.
9. Latorre C, Sierra M, Lite J. Prospective study of the invasive strains of Streptococcus pneumoniae isolated in 16 hospitals in Catalonia, Spain. Enferm Infecc Microbiol Clin 1999;17:286-91.
10. Fenoll A, Jado I, Vicioso D, et al. Streptococcus pneumoniae in children in Spain: 1990-1999. Acta Pediatr 2000;89:44-50.
11. Domingo A, et al. Abstract Book of the 19th Annual Meeting of the European Society for Pediatric Infectious Diseases; Istanbul, Turkey, 2001.
12. Spika JS, Kertesz D, Deeks S, Talbot J. Pneumococcal infection and anti-pneumococcal vaccination programs in Canada. Presse Med 1998;27(Suppl. 1):S39-42.
13. Zangwill KM, Vadheim CM, Vannier AM, et al. Epidemiology of invasive pneumococcal disease in southern California: implications for the design and conduct of a pneumococcal conjugate vaccine efficacy trial. J Infect Dis 1996;17:752-9.
14. Casado Flores J, Garcia Teresa MA, Cambra F, et al. Multicenter prospective study on severe bacterial meningitis in children. An Esp Pediatr 1997;47:466-72.
15. Alonso Palacio J, Madrigal Diez V, Garcia Fuentes M. Pneumococcal meningitis in the infantile population of Cantabria. An Esp Pediatr 1992;36:441-5.
16. Morant A, Diez J, Gimeno C, et al. Epidemiology of haemophilus influenzae type B, Neisseria meningitidis, and Streptococcus pneumoniae in children in the Valencia community. Spain Rev Neurol 1998;26:34-7.
17. Casado Flores J, Aristegui J, Rodrigo C, et al. Prevalence pneumococcal meningitis in Spanish children. An Esp Pediatr 2002;56:5-9.
18. WHO. Report of the Technical Review Group Meeting; Geneva, Switzerland, 1998 Jun 7-8.
19. McCracken GH Jr. Etiology and treatment of pneumonia. Pediatr Infectious Dis J 2000;19:373-7.
20. Tristam DA, Miller RW, McMillan JA, Weiner LB. Simultaneous infection with respiratory syncytial virus and other respiratory pathogens. Am J Dis Child 1988;142:834-6.
21. Korppi M, Leinonen M, Koskela M, et al. Bacterial coinfection in children hospitalized with respiratory syncytial virus infections. Pediatr Infect Dis J 1989;8:687-92.
22. Romero Vivas J, Rubio Alonso M, Corral O, et al. Study of extrahospitalary respiratory infections. Enferm Infecc Microbiol Clin 1997;15:289-98.
23. Luotonen J, Herva E, Karma P, et al. The bacteriology of acute otitis media in children with special reference to Streptococcus pneumoniae as studied by bacteriological and antigen detection methods. Scand J Infect Dis 1982;13:177-83.
24. Del Castillo F, Barrio Gomez MI, Garcia A. Bacteriologic study of 80 cases of acute otitis media in children. Enferm Infecc Microbiol Clin 1994;12:82-5.
25. Riquelme Perez M, Gasquez Abad CI, Mena Mateo E, Mugurza Hernandez D. Acute otitis media in a pediatrics consulting office. An Esp Pediatr 1996;44:433-6.
26. Teele DW, Klein JO, Rosner B. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J Infect Dis 1989;160:83-94.
27. Fenoll A, Jado I, Vicioso D, et al. Evolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Spain: update (1990-1996). Clin Microbiol 1998;36:3447-54.
28. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-38.
29. Beck JR, Kassirer JP, Pauker SG. The convenient approximation of life expectancy (the "deale"). II. Use in medical decision making. Am J Med 1982;73:889-97.
30. World Population Prospects: The 1998 Revision. New York: United Nations Population Division, 1998.
31. The World Factbook. Washington (DC): CIA, 2003. http://www.cia.gov/cia/publications/factbook/.
32. Diez Domingo J, Morant A, Pereiro I, et al. Childhood invasive pneumococcal disease in Valencia, Spain: population based surveillance system. In: Abstract Book of the 17th Annual Meeting of the European Society for Pediatric Infectious Diseases; Heraklion, Greece 1999:2.
33. Fenoll A, Jado I, Vicioso D, et al. Streptococcus pneumoniae in children in Spain. 1990-1999. Acta Paediatr 2000;435(Suppl):S44-50.
34. Eskola J, Kilpi T. Efficacy of a Heptavalent Pneumococcal Conjugate Vaccine (PncCRM) against Serotype-Specific, Culture-Confirmed Pneumococcal Acute Otitis Media (AOM) in Infants and Children. Paper presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; Moscone Center, San Francisco, CA; Abstract LB-13.
35. Pukander J, Luotonen J, Sipila M, et al. Incidence of acute otitis media. Acta Otolaryngol 1982;93:447-53.
36. Eskola J, Anttila M. Pneumococcal conjugate vaccines. Pediatr Infect Dis J 1999;18:543-51.
37. Barbour ML, Booy R, Crook DWM, et al. Haemophilus influenzae type b carriage and immunity four years after receiving the haemophilus influenzae oligosaccharide-CRM197 (HbOC) conjugate vaccine. Pediatr Infect Dis J 1993;12:478-84.
38. Resultados de la Gestion Analitica en los Hospitales del INSALUS, 1998. Madrid: Instituto Naciaonal de la Salud, 1999.
39. Medicom. 'VADEMECUM' Catalogo de Especialidades Farmaceuticas. Madrid: Consejo General de Colegios Oficiales de Farmaceuticos, 1998.
40. Capra A. The cost of otitis media. Pediatr Infect Dis J 2000;19:354-5.
41. National Statistics Institute [Internet]. Madrid: The Institute; c2003. Available from: http://www.ine.es/.
42. Guillen Grima F, Espin Rios MI. Cost-effectiveness analysis of different alternatives of universal vaccination against hepatitis B in the region of Murcia. Med Clin (Barc) 1995;104:130-6.
43. Arnal JM, Frisas O, Garuz R, Antonanzas F. Cost effectiveness of hepatitis A virus immunisation in Spain. Pharmacoeconomics 1997;12:361-73.
44. Briggs AH, Gray AM. Handling uncertainty when performing economic evaluation of healthcare interventions. Health Technol Assess 1999;3:635-8.
45. Chapman RH, Stone PW, Sandberg EA, et al. A comprehensive league table of cost-utility ratios and a sub-table of "panel-worthy" studies. Med Decis Making 2000;20:451-67.
46. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473-81.
47. Ryan KJm et al. Sherris Medical Microbiology: An Introduction to Infectious Diseases. 3rd ed. Cincinnati: McGraw-Hill, 1994.
48. Murphy TV, Pastor P, Medley F, et al. Decreased haemophilus colonization in children vaccinated with haemophilus influenzae type b conjugate vaccine. J Pediatr 1993;122(Suppl):S17-23.
49. Lebel MH, Kellner JD, Ford-Jones LE, et al. A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada. Clin Infect Dis 2003;36:259-68.
50. Markowitz JS, Pashko S, Gutterman EM, et al. Death rates among patient hospitalized with community-acquired pneumonia: a re-examination with data from three states. Am J Public Health 1996;86:1152-4.
51. Afeesa B, Greaves WL, Frederick WR. Pneumococcal bacteremia in adults: a 14-year experience in an inner-city university hospital. Clin Infect Dis 1995;21:345-51.
52. King JC, Vink PE, Farley JJ, et al. Safety and immunogenicity of three doses of a five-valent pneumococcal conjugate vaccine in children younger than two years with and without human immunodeficiency virus infection. Pediatrics 1997;99:575-80.
53. King JC, Vink PE, Farley JJ, et al. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children. Pediatr Infect Dis J 1996;15:192-6.